Short answer
Sana Biotechnology, Inc. (SANA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Sana Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Detailed results and management commentary contained in Exhibit 99.1, the accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- Cash $121.7M at September 30, 2026, with runway into mid-2027, but nine-month non-GAAP operating cash burn reached $103.4M
- SC451 IND and Phase 1/2 trial targeted as early as 2026, creating a near-term clinical catalyst in type 1 diabetes
- SG293 clinical study in non-Hodgkin lymphoma targeted for 1Q 2027, with first-in-human data potentially in the first half of 2027
- UP421 showed 14-month beta-cell survival and function without immunosuppression, supporting Sana’s HIP platform while remaining single-patient evidence
- Q3 GAAP net income $20.4M reflected $63.4M of non-cash liability valuation gains, while non-GAAP net loss was $43.0M###
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sana Biotechnology, Inc. 8-K filings
Get the next SANA 8-K as it lands
Follow SANA for push alerts, or ask the research agent what this filing means.